Market Cap | 6.11B | P/E | 29.99 | EPS this Y | 22.80% | Ern Qtrly Grth | -45.00% |
Income | 40.67M | Forward P/E | 22.70 | EPS next Y | 16.80% | 50D Avg Chg | 2.00% |
Sales | 2.24B | PEG | 1.49 | EPS past 5Y | 17.20% | 200D Avg Chg | -5.00% |
Dividend | N/A | Price/Book | 3.13 | EPS next 5Y | 16.60% | 52W High Chg | -25.00% |
Recommedations | 2.20 | Quick Ratio | 1.39 | Shares Outstanding | 112.98M | 52W Low Chg | 17.00% |
Insider Own | 0.77% | ROA | 6.11% | Shares Float | 111.99M | Beta | 1.18 |
Inst Own | 102.67% | ROE | 1.37% | Shares Shorted/Prior | 3.53M/4.39M | Price | 59.69 |
Gross Margin | 67.66% | Profit Margin | 1.82% | Avg. Volume | 999,509 | Target Price | 79.31 |
Oper. Margin | 18.72% | Earnings Date | Nov 5 | Volume | 967,746 | Change | 1.20% |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Pfeil Keith W | SVP, Chief Financial.. SVP, Chief Financial Officer | Feb 02 | Sell | 77.57 | 29,167 | 2,262,484 | 02/06/23 | |
Pfeil Keith W | SVP, Chief Financial.. SVP, Chief Financial Officer | Feb 02 | Option | 51.46 | 29,167 | 1,500,934 | 29,167 | 02/06/23 |
Pfeil Keith W | SVP, Chief Financial.. SVP, Chief Financial Officer | Aug 19 | Sell | 76.13 | 833 | 63,416 | 02/06/23 | |
Pfeil Keith W | SVP, Chief Financial.. SVP, Chief Financial Officer | Aug 19 | Option | 49.65 | 833 | 41,358 | 833 | 02/06/23 |
Davidar David D | Director Director | Apr 19 | Sell | 78.034 | 31,500 | 2,458,071 | 601,275 | 04/21/22 |
Huller Kelly | SVP, GC, Corporate S.. SVP, GC, Corporate Secretary | Apr 08 | Option | 15.34 | 2,500 | 38,350 | 2,500 | 04/11/22 |
Huller Kelly | SVP, GC, Corporate S.. SVP, GC, Corporate Secretary | Apr 08 | Sell | 75.59 | 2,500 | 188,975 | 04/11/22 | |
TOBIN JAMES R | Director Director | Mar 08 | Sell | 71.02 | 14,484 | 1,028,654 | 03/10/22 | |
TOBIN JAMES R | Director Director | Mar 08 | Option | 43.58 | 14,484 | 631,213 | 10,000 | 03/10/22 |
Pfeil Keith W | SVP, Chief Financial.. SVP, Chief Financial Officer | Aug 23 | Sell | 76.13 | 833 | 63,416 | 08/23/21 | |
Pfeil Keith W | SVP, Chief Financial.. SVP, Chief Financial Officer | Aug 23 | Option | 53.27 | 833 | 44,374 | 833 | 08/23/21 |
Lemaitre Dan | Director Director | Mar 11 | Option | 11.28 | 15,384 | 173,532 | 15,384 | 03/11/21 |
Lemaitre Dan | Director Director | Mar 11 | Sell | 62.47 | 15,384 | 961,038 | 03/11/21 | |
Huller Kelly | SVP, GC, Corporate S.. SVP, GC, Corporate Secretary | Dec 29 | Option | 11.28 | 2,000 | 22,560 | 2,000 | 12/29/20 |
Huller Kelly | SVP, GC, Corporate S.. SVP, GC, Corporate Secretary | Dec 29 | Sell | 66.15 | 2,000 | 132,300 | 12/29/20 | |
Demski David M | President, CEO President, CEO | Dec 18 | Option | 38.89 | 330,000 | 12,833,700 | 478,855 | 12/18/20 |
Demski David M | President, CEO President, CEO | Dec 18 | Sell | 56.23 | 330,000 | 18,555,900 | 148,855 | 12/18/20 |